Press Releases

Date Title and Summary
May 10, 2022

Catalyst Pharmaceuticals Reports Record First Quarter 2022 Financial Results And Provides Corporate Update

Achieved Record Revenues of more than $43 Million , a 42.7% Increase YoY Three New Patents Issued; Now Five Orange-Book Listed Patents for FIRDAPSE ® Significant Cash Position of $198 Million and No Funded Debt Advanced Plans to Diversify and Invest in Innovative Rare Disease Opportunities
Apr 25, 2022

Catalyst Pharmaceuticals to Report First Quarter 2022 Financial Results on May 10, 2022

The Company to Host a Conference Call and Webcast on May 11, 2022, at 8:30 AM ET CORAL GABLES, Fla. , April 25, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals , Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing
Mar 16, 2022

Catalyst Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

Total 2021 Revenues Increased Approximately 18% YoY to $141 Million Strong 2022 Revenue Growth Expected, Supported by FIRDAPSE ® Orphan Drug Exclusivity New Patent Issuances Strengthens FIRDAPSE Long-Term Commercial Potential to 2034 Actively Pursuing Opportunities to Diversify Commercial and
Mar 11, 2022

Catalyst Pharmaceuticals and KYE Pharmaceuticals Announce a Second Favorable Canadian Federal Court Ruling Setting Aside Approval of Ruzurgi®

CORAL GABLES, Fla. , March 11, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare
Mar 08, 2022

Catalyst Pharmaceuticals Named Among Forbes 2022 America's Best Small Companies

The Company Ranked 65th of More Than 1,000 Companies Assessed CORAL GABLES, Fla. , March 08, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals , Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing
Mar 03, 2022

Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2021 Financial Results on March 16, 2022

The Company Will Host a Conference Call and Webcast on March 17, 2022, at 8:30 AM ET CORAL GABLES, Fla. , March 03, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals , Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing,
Mar 02, 2022

Catalyst Pharmaceuticals Further Strengthens FIRDAPSE® U.S. Patent Portfolio

Three New Patents Covering Additional Patient Amifampridine Metabolizer Types have been Allowed and will Issue in March 2022 Reinforces and Diversifies FIRDAPSE Long-Term Patent Portfolio Patent Portfolio Provides Intellectual Property Protection Until 2034 CORAL GABLES, Fla.
Feb 24, 2022

Catalyst Pharmaceuticals Teams Up with Patients and Advocacy Groups to Ring Nasdaq Opening Bell on Rare Disease Day 2022

Ceremony Recognizes Importance of Biopharma Industry and Advocacy Group Collaboration to Address Needs for New Treatments in Orphan and Rare Disorders Together, Will Ring the Nasdaq Opening Bell to Kick-Off Rare Disease Day on February 28, 2022 CORAL GABLES, Fla. , Feb.
Feb 17, 2022

Catalyst Pharmaceuticals to Launch LEMS Aware Podcast on Rare Disease Day 2022

Initiative Part of Expansion of Education and Awareness Activities for Lambert-Eaton Myasthenic Syndrome Community CORAL GABLES, Fla. , Feb. 17, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused
Feb 07, 2022

Catalyst Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2021 Total Revenues; Provides 2022 Total Revenue Guidance and Corporate Update

2021 Total Revenues Estimated at $141 Million , Representing 18% YoY Growth Forecast 2022 Total Revenues of Between $195 Million and $205 Million , Representing YoY Growth of 38% to 45% Recently Regained Orphan Drug Exclusivity in the U.S. for Amifampridine to Treat LEMS Entering 2022 with a Strong

Displaying 11 - 20 of 24